HR and breast cancer: Recently, the prospective ECOG-ACRIN Trial Assigning Individualized Options for Treatment (TAILORx) established in over 10,000 patients that the vast majority of HR+, HER2−, node-negative (N0) primary BC patients (about to 80%) do not derive benefit from CT in terms of recurrence risk6.